Although cardiovascular patients taking proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to achieve very low levels of cholesterol do not experience an increase of some adverse events, they may have an increased risk for cataracts (J Am Coll Cardiol 2016 Jan 31. [Epub ahead of print]).
Statins are used largely to lower low-density lipoprotein cholesterol—the bad cholesterol—and prevent cardiovascular disease. However, some patients need to reduce